Tesamorelin vs Sermorelin: The Difference

The core difference is this: sermorelin is the GHRH(1-29) fragment, the minimal portion of growth hormone-releasing hormone (GHRH) that retains biological activity, while tesamorelin is an analog of the full GHRH(1-44) molecule modified with a trans-3-hexenoic acid group at the N-terminus to resist enzymatic degradation. Both activate the same receptor, but they are not the same amino acid sequence and they do not have the same stability in solution, and those two differences account for almost everything a comparison between them turns up.

If you're trying to work out why a research catalogue lists them as two separate peptides rather than interchangeable variants, the answer sits in the structure, not in the trade name.

The structural difference between tesamorelin and sermorelin

Native human GHRH is a 44-amino-acid peptide. It was established decades ago that the fragment corresponding to the first 29 residues — GHRH(1-29) — retains the full functional activity of the complete molecule. That fragment, synthesized and stabilized as an acetate salt, is sermorelin.

Tesamorelin starts from the same sequence logic but keeps the full 44-amino-acid chain, and adds a trans-3-hexenoic acid group at the N-terminus. That group acts as protection: it makes it harder for the enzyme dipeptidyl peptidase-4 (DPP-4) to cleave the peptide as soon as it contacts plasma, which is the main mechanism by which native GHRH and sermorelin degrade quickly in aqueous solution.

That is the difference that explains everything else: two molecules related by function, with different chain lengths and different chemical stability.

What sermorelin is: the minimal active fragment

Sermorelin is studied as the shortest GHRH fragment capable of stimulating the GHRH-receptor pathway in the pituitary. In the literature it is usually described as a tool for investigating the GHRH-GH-IGF-1 axis without working with the full 44-amino-acid molecule, which is more expensive to synthesize and less stable in solution.

Because of its smaller size, in vitro studies on sermorelin tend to focus on receptor-binding kinetics and on models of pituitary growth hormone secretion, rather than on plasma pharmacokinetics — which is where tesamorelin has most of its published literature.

You can see the full technical sheet — molecular weight, formula, and batch documentation — on the sermorelin product page.

What tesamorelin is: the stabilized analog of full-length GHRH

Tesamorelin sourced for Argentina is studied primarily for that added stability. The trans-3-hexenoic acid group doesn't change the part of the molecule that interacts with the receptor: it changes how long the molecule survives intact before being degraded. That makes it a different model for pharmacokinetic studies, because it allows researchers to observe a longer window of plasma activity than the unmodified GHRH(1-29) fragment provides.

That's also why, in a number of countries, tesamorelin came to be authorized for clinical use under prescription in specific indications — a regulatory chapter separate from its use as a research reference material, and one that doesn't change anything about its classification in an RUO catalogue.

Why plasma half-life is not a minor detail

When the literature compares GHRH(1-29) against stabilized analogs such as tesamorelin, the comparison point is almost always plasma half-life: how long the intact peptide stays detectable before it degrades. Sermorelin, lacking N-terminal protection, has a shorter half-life in the published models. Tesamorelin, with the trans-3-hexenoic acid group, shows slower degradation.

That difference is what a researcher needs to account for when designing an experimental protocol, because it determines how long the system under study is exposed to the active peptide. It is not a difference in potency, and not a question of "which one works better" — it is a difference in chemical stability, measurable as the time it takes the molecule to break down in solution.

What the studies on each peptide measure

The literature on GHRH(1-29) and its analogs concentrates on three recurring lines of inquiry:

• Binding to the GHRH receptor and activation of the signaling pathway that regulates pituitary growth hormone release.
• Enzymatic stability against DPP-4 and other plasma proteases, which is where tesamorelin diverges from both sermorelin and native GHRH.
• Body composition models and visceral adipose tissue distribution, an area where tesamorelin holds a substantial share of its published literature.

None of those three lines constitutes a use indication for a person. They are lines of research in experimental models, and that is how they are cited in the papers that describe them.

Documentation and traceability when sourcing to Argentina

A research peptide isn't distinguished by the name printed on the label — it's distinguished by the laboratory report that backs that specific batch. Before comparing tesamorelin and sermorelin on their technical specs, it's worth checking what documentation accompanies the material: an HPLC purity report, identity confirmed by mass spectrometry, and batch traceability back to the laboratory that ran the analysis.

That's the basis on which any quote to a destination such as Argentina is built: the import file is prepared identifying the material as laboratory reference material, with the batch's technical documentation attached. You can see how that documentation is organized on the quality page, and review the rest of the compounds available for quoting in the full catalogue.

For laboratory research use only

Tesamorelin and sermorelin, like every other peptide listed on this site, are supplied strictly as reference material for in vitro and laboratory research (Research Use Only). Neither product is approved, or intended, for human or veterinary consumption, for diagnosis, or for treatment, and none of the statements on this page have been evaluated by ANMAT, the FDA, or any equivalent authority. No guidance on administration, protocols, or human use is provided, and inquiries about that kind of use are declined.